Molecular, Cellular, and Tissue Characterization Unit
分子、细胞和组织表征单元
基本信息
- 批准号:10461044
- 负责人:
- 金额:$ 98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-30 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Adjuvant TherapyAntibodiesApoptosisAtlasesBiopsyCell ProliferationCellsClinical DataCollectionComplementCoupledCytometryDNADataData AnalysesData SetDiagnosisDiffusionDiseaseDisseminated Malignant NeoplasmElementsEvaluationExcisionFutureGlioblastomaGoalsHistologyHumanImageImaging technologyImmuneImmune TargetingImmunofluorescence ImmunologicImmunotherapyIndividualLinkLocationMagnetic Resonance ImagingMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of brainMalignant neoplasm of gastrointestinal tractMalignant neoplasm of pancreasMetadataMetastatic toMissionMolecularNatureNeoadjuvant TherapyNeoplasm MetastasisNon-MalignantOperative Surgical ProceduresPancreatic Ductal AdenocarcinomaPatient RecruitmentsPatientsPhenotypePrimary NeoplasmProceduresPrognosisProteinsRNARecurrenceResearchResearch PersonnelResistanceResistance developmentSamplingSignal TransductionSiteSlideSpecimenStromal CellsStructureTechnologyTimeTissuesTrainingTumor-infiltrating immune cellsUniversitiesWashingtonWorkaggressive breast cancerbasecancer stem cellcancer typecellular imagingdesignin vivoinsightmolecular phenotypemultidimensional datamultiplexed imagingneoplastic cellnew technologynoveloptical imagingpatient responseprotein activationprotein metaboliteradiomicsresponsesingle cell analysissingle-cell RNA sequencingtherapeutic developmenttherapy resistanttraditional therapytranscriptome sequencingtreatment responsetriple-negative invasive breast carcinomatumortumor microenvironment
项目摘要
Project Summary/Abstract: Biospecimen Unit
The over-arching goal of the Biospecimen Unit for the Washington University Human Tumor Atlas Research
Center (WU-HTARC) is to collect human tumor biospecimens for use by the Characterization and Data
Analysis Units to construct the proposed tumor atlases. Our Biospecimen Unit will procure and bank
longitudinal biopsies and excised tumors from 300-375 patients (selected from ~750 recruited patients) with a
goal toward studying the transition from primary malignancy to recurrence and metastasis in conjunction with
the development of therapeutic resistance in triple negative breast cancer (TNBC), glioblastoma (GBM), and
pancreatic ductal adenocarcinoma (PDAC). Each of the three tumors chosen for this study poses unique
challenges for both clinicians and researchers. From their often late onset of diagnosis, highly metastatic
nature, challenges in achieving complete surgical resection, and primary and acquired resistance to treatment,
each of these tumors represents an opportunity identified by the NCI Cancer Moonshot Initiative (CMI) to
significantly advance our understanding of cancer and how to intervene on its initiation and progression. To
support the overall mission of WU-HTARC, the Biospecimen Unit will perform the following: (1) identification of
eligible patients at WU with TNBC, GBM, and PDAC; (2) rigorous and systemic collection of tumors, including
longitudinal collection of all patients throughout their treatment course; (3) complete collection of associated
clinical data and metadata; and (4) storage and processing of all samples with current and future experimental
and analytical pipelines. The Biospecimen Unit will work closely with other Units within WU-HTARC to develop
standard operating procedures and to make adjustments in line with the changing technologies.
项目概要/摘要:生物标本单元
华盛顿大学人类肿瘤图谱研究生物标本组的超额目标
中心(WU-HTARC)将采集人类肿瘤生物标本,供表征和数据分析使用
分析单元,以构建拟定的肿瘤图谱。我们的生物样本组将从
来自300-375名患者(选自约750名招募的患者)的纵向活检和切除的肿瘤,
目的是研究从原发性恶性肿瘤到复发和转移的转变,
三阴性乳腺癌(TNBC)、胶质母细胞瘤(GBM)和
胰腺导管腺癌(PDAC)。本研究选择的三种肿瘤中的每一种都具有独特的
对临床医生和研究人员的挑战。从他们往往迟发诊断,高度转移
性质,实现完全手术切除的挑战,以及对治疗的原发性和获得性抵抗,
这些肿瘤中的每一个都代表了NCI癌症登月计划(CMI)确定的机会,
大大提高了我们对癌症以及如何干预其发生和发展的认识。到
为了支持WU-HTARC的总体使命,生物标本股将执行以下任务:(1)识别
符合条件的WU TNBC、GBM和PDAC患者;(2)严格和系统性收集肿瘤,包括
在整个治疗过程中纵向收集所有患者;(3)完整收集相关的
临床数据和元数据;以及(4)存储和处理具有当前和未来实验的所有样品。
和分析管道。生物标本股将与WU-HTARC内的其他单位密切合作,
标准作业程序,并根据不断变化的技术作出调整。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William E. Gillanders其他文献
Landscape of cancer associated EpCAM mutations: molecular modeling, predictive insights and impact on patient survival
- DOI:
10.1186/s12885-025-14455-8 - 发表时间:
2025-07-01 - 期刊:
- 影响因子:3.400
- 作者:
Priyanka S. Dhotare;Audrey C. Bochi-Layec;Timothy P. Fleming;William E. Gillanders;Ross M. Bremner;Kailas D. Sonawane;Narendra V. Sankpal - 通讯作者:
Narendra V. Sankpal
Molecular characteristics of isthmus papillary thyroid cancers: Supporting evidence for unfavorable clinical behavior
- DOI:
10.1016/j.amjsurg.2023.09.005 - 发表时间:
2024-02-01 - 期刊:
- 影响因子:
- 作者:
Eileen R. Smith;C. Corbin Frye;T.K. Pandian;William E. Gillanders;John A. Olson;Taylor C. Brown;Sina Jasim - 通讯作者:
Sina Jasim
Micrometastatic Disease and Isolated Tumor Cells as a Predictor for Additional Breast Cancer Axillary Metastatic Burden
- DOI:
10.1245/s10434-010-1255-1 - 发表时间:
2010-09-19 - 期刊:
- 影响因子:3.500
- 作者:
Amy Cyr;William E. Gillanders;Rebecca L. Aft;Timothy J. Eberlein;Feng Gao;Julie A. Margenthaler - 通讯作者:
Julie A. Margenthaler
Predictors of Primary Breast Abscesses and Recurrence
- DOI:
10.1007/s00268-009-0170-8 - 发表时间:
2009-08-08 - 期刊:
- 影响因子:2.500
- 作者:
Ankit Bharat;Feng Gao;Rebecca L. Aft;William E. Gillanders;Timothy J. Eberlein;Julie A. Margenthaler - 通讯作者:
Julie A. Margenthaler
Best practices for bioinformatic characterization of neoantigens for clinical utility
- DOI:
10.1186/s13073-019-0666-2 - 发表时间:
2019-08-28 - 期刊:
- 影响因子:11.200
- 作者:
Megan M. Richters;Huiming Xia;Katie M. Campbell;William E. Gillanders;Obi L. Griffith;Malachi Griffith - 通讯作者:
Malachi Griffith
William E. Gillanders的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William E. Gillanders', 18)}}的其他基金
Molecular, Cellular, and Tissue Characterization Unit
分子、细胞和组织表征单元
- 批准号:
10904040 - 财政年份:2023
- 资助金额:
$ 98万 - 项目类别:
Targeting Neoantigens in Triple Negative Breast Cancer
针对三阴性乳腺癌的新抗原
- 批准号:
9980320 - 财政年份:2019
- 资助金额:
$ 98万 - 项目类别:
Targeting Neoantigens in Triple Negative Breast Cancer
针对三阴性乳腺癌的新抗原
- 批准号:
10458605 - 财政年份:2019
- 资助金额:
$ 98万 - 项目类别:
Targeting Neoantigens in Triple Negative Breast Cancer
针对三阴性乳腺癌的新抗原
- 批准号:
10675496 - 财政年份:2019
- 资助金额:
$ 98万 - 项目类别:
Targeting Neoantigens in Triple Negative Breast Cancer
针对三阴性乳腺癌的新抗原
- 批准号:
10224142 - 财政年份:2019
- 资助金额:
$ 98万 - 项目类别:
Molecular, Cellular, and Tissue Characterization Unit
分子、细胞和组织表征单元
- 批准号:
10242184 - 财政年份:2018
- 资助金额:
$ 98万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 98万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 98万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 98万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 98万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 98万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 98万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 98万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 98万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 98万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 98万 - 项目类别: